Inovio Pharmaceuticals Targets Transformation of Monoclonal Antibody Therapies

In this study in mice, a prototype monoclonal antibody construct encoding for an established anti-HIV monoclonal antibody was created as a DNA plasmid using Inovio's patented DNA optimization technology, including codon/RNA optimization and leader sequence utilization, and delivered with its CELLECTRAA adaptive electroporation device.

http://www.sys-con.com/node/2804871